A study has demonstrated that the inherited risk of early-onset cancer is significantly higher among Latino and African American families for solid tumors, and Asian/Pacific Islander families for blood-based cancers, compared to non-Latino white families in California.
Cancer immunotherapy involving drugs that inhibit CTLA-4 also activates an unwanted response that may self-limit its efficacy in fighting tumors, according to a new study led by Francesco Marangoni.
A study led by Yale Cancer Center scientists revealed the combination of ATR and PARP inhibitor therapies can effectively target the enzyme isocitrate dehydrogenase-I/2 (IDH-1/2) in mutant cancer cells.
A study by researchers at Yale Cancer Center shows that combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
A study led by Yale Cancer Center researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.
The Pancreatic Cancer Action Network has added another treatment arm by biopharmaceutical company FibroGen Inc. to its clinical trial platform, Precision Promise.
Data from three pivotal phase III studies—CLL14, MURANO and VIALE-A—of Venclexta (venetoclax) support the primary analysis of Venclexta in chronic lymphocytic leukemia and the possibility of tailoring treatment approaches based on genetic risk factors.
In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg-Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
Salk researchers, led by Susan Kaech, have found that the tumor microenvironment contains an abundance of oxidized fat molecules, which, when ingested by the killer T cells, suppresses their ability to kill cancer cells.
